TY - JOUR
T1 - Characterization of the commercially-available fluorescent chloroquine-BODIPY conjugate, LynxTag- CQGREEN, as a marker for chloroquine resistance and uptake in a 96-well plate assay
AU - Loh, Cheryl C.Y.
AU - Suwanarusk, Rossarin
AU - Lee, Yan Quan
AU - Chan, Kitti W.K.
AU - Choy, Kit Ying
AU - Rénia, Laurent
AU - Russell, Bruce
AU - Lear, Martin J.
AU - Nosten, Francois H.
AU - Tan, Kevin S.W.
AU - Chow, Ming Cheung
PY - 2014/10/24
Y1 - 2014/10/24
N2 - Chloroquine was a cheap, extremely effective drug against Plasmodium falciparum until resistance arose. One approach to reversing resistance is the inhibition of chloroquine efflux from its site of action, the parasite digestive vacuole. Chloroquine accumulation studies have traditionally relied on radiolabelled chloroquine, which poses several challenges. There is a need for development of a safe and biologically relevant substitute. We report here a commercially-available green fluorescent chloroquine-BODIPY conjugate, LynxTag-CQGREEN, as a proxy for chloroquine accumulation. This compound localized to the digestive vacuole of the parasite as observed under confocal microscopy, and inhibited growth of chloroquine-sensitive strain 3D7 more extensively than in the resistant strains 7G8 and K1. Microplate reader measurements indicated suppression of LynxTag-CQGREENefflux after pretreatment of parasites with known reversal agents. Microsomes carrying either sensitiveor resistant-type PfCRT were assayed for uptake; resistant-type PfCRT exhibited increased accumulation of LynxTag-CQGREEN, which was suppressed by pretreatment with known chemosensitizers. Eight laboratory strains and twelve clinical isolates were sequenced for PfCRT and Pgh1 haplotypes previously reported to contribute to drug resistance, and pfmdr1 copy number and chloroquine IC50s were determined. These data were compared with LynxTag-CQGREENuptake/fluorescence by multiple linear regression to identify genetic correlates of uptake. Uptake of the compound correlated with the logIC50of chloroquine, more weakly, a mutation in Pgh1, F1226Y.
AB - Chloroquine was a cheap, extremely effective drug against Plasmodium falciparum until resistance arose. One approach to reversing resistance is the inhibition of chloroquine efflux from its site of action, the parasite digestive vacuole. Chloroquine accumulation studies have traditionally relied on radiolabelled chloroquine, which poses several challenges. There is a need for development of a safe and biologically relevant substitute. We report here a commercially-available green fluorescent chloroquine-BODIPY conjugate, LynxTag-CQGREEN, as a proxy for chloroquine accumulation. This compound localized to the digestive vacuole of the parasite as observed under confocal microscopy, and inhibited growth of chloroquine-sensitive strain 3D7 more extensively than in the resistant strains 7G8 and K1. Microplate reader measurements indicated suppression of LynxTag-CQGREENefflux after pretreatment of parasites with known reversal agents. Microsomes carrying either sensitiveor resistant-type PfCRT were assayed for uptake; resistant-type PfCRT exhibited increased accumulation of LynxTag-CQGREEN, which was suppressed by pretreatment with known chemosensitizers. Eight laboratory strains and twelve clinical isolates were sequenced for PfCRT and Pgh1 haplotypes previously reported to contribute to drug resistance, and pfmdr1 copy number and chloroquine IC50s were determined. These data were compared with LynxTag-CQGREENuptake/fluorescence by multiple linear regression to identify genetic correlates of uptake. Uptake of the compound correlated with the logIC50of chloroquine, more weakly, a mutation in Pgh1, F1226Y.
UR - http://www.scopus.com/inward/record.url?scp=84908425701&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0110800
DO - 10.1371/journal.pone.0110800
M3 - Journal article
C2 - 25343249
SN - 1932-6203
VL - 9
JO - PLoS ONE
JF - PLoS ONE
IS - 10
M1 - e110800
ER -